CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV
Companies enter into a collaboration and services agreement / Bayer to support CureVac in numerous areas, including development and supply of CVnCoV / CureVac benefits from Bayer´s expertise and established infrastructure / Plan to facilitate the supply of several hundred million doses
Berlin and Tübingen, Germany / Boston, USA, January 7, 2021 – Bayer has signed a collaboration and services agreement with CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA). Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac´s COVID-19 vaccine candidate CVnCoV. To this end, Bayer will contribute its expertise and established infrastructure in areas such as clinical operations, regulatory affairs, pharmacovigilance, medical information, supply chain
CureVac and Bayer team up to advance COVID-19 vaccine candidate Pharmaceutical giant Bayer will support development of CureVac’s mRNA COVID-19 vaccine candidate across numerous areas: helping facilitate the global supply of several hundred million doses.
CureVac – whose vaccine candidate CVnCoV headed into Phase 3 trials in December – will benefit from Bayer’s expertise and established infrastructure as it takes the vaccine forward through clinical trials, authorization and mass production and supply.
The collaboration and services agreement will see Bayer support fellow German company and mRNA specialist CureVac in further development, supply and key territory operations of the vaccine candidate. This includes areas such as clinical operations, regulatory affairs, pharmacovigilance, medical information and supply chain performance.
DGAP-News: CureVac / Key word(s): Alliance/Agreement
CureVac : CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV
07.01.2021 / 08:30
CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV
- Companies enter into a collaboration and services agreement
- Bayer to support CureVac in numerous areas, including development and supply of CVnCoV
- CureVac benefits from Bayer s expertise and established infrastructure
- Plan to facilitate the supply of several hundred million doses
Berlin and Tübingen, Germany/ Boston, USA, January 7, 2021 -
Bayer has signed a collaboration and services agreement with CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA). Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac s COVID-19 vaccine candidate CVnCoV. To this end, Bayer will contribute its exper